This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Phan, D. D.
Right arrow Articles by Guglielmo, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Phan, D. D.
Right arrow Articles by Guglielmo, B. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2003, p. 2351-2353, Vol. 47, No. 7
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.7.2351-2353.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Intra- and Interindividual Variabilities of Valacyclovir Oral Bioavailability and Effect of Coadministration of an hPEPT1 Inhibitor

Dana D. Phan,1 Peter Chin-Hong,2 Emil T. Lin,1 Pascale Anderle,1,{dagger} Wolfgang Sadee,1,{ddagger} and B. Joseph Guglielmo1*

Schools of Pharmacy,1 Medicine, University of California, San Francisco, California2

Received 22 November 2002/ Returned for modification 17 March 2003/ Accepted 24 April 2003

Variability in valacyclovir bioavailability and the potential for cephalexin-valacyclovir interaction were evaluated. The intraindividual acyclovir area under the concentration-time curve (AUC) varied minimally, whereas interindividual differences were substantial. Coadministration of the human peptide transporter 1 (hPEPT1) substrates valacyclovir and cephalexin minimally reduced the acyclovir AUC. These results suggest a stable valacyclovir absorption phenotype, significant interindividual variability, and minimal interaction between these hPEPT1 substrates.

* Corresponding author. Mailing address: Department of Clinical Pharmacy, Box 0622, C-144, University of California at San Francisco, San Francisco, CA 94143. Phone: (415) 476-1927. Fax: (415) 476-6632. E-mail: bjg{at}itsa.ucsf.edu.

{dagger} Present address: ISREC, 1066 Epalinges, Switzerland.

{ddagger} Present address: Ohio State University, Columbus, OH 43210.

Antimicrobial Agents and Chemotherapy, July 2003, p. 2351-2353, Vol. 47, No. 7
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.7.2351-2353.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Foster, D. R., Yee, S., Bleske, B. E., Carver, P. L., Shea, M. J., Menon, S. S., Ramachandran, C., Welage, L. S., Amidon, G. L. (2009). Lack of Interaction Between the Peptidomimetic Substrates Captopril and Cephradine. J Clin Pharmacol 49: 360-367 [Abstract] [Full Text]  
  • Anderle, P., Nielsen, C. U., Pinsonneault, J., Krog, P. L., Brodin, B., Sadee, W. (2006). Genetic Variants of the Human Dipeptide Transporter PEPT1. J. Pharmacol. Exp. Ther. 316: 636-646 [Abstract] [Full Text]  
  • MacDougall, C., Guglielmo, B. J. (2004). Pharmacokinetics of valaciclovir. J Antimicrob Chemother 53: 899-901 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»